A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis

NCT ID: NCT04222712

Last Updated: 2023-10-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-01

Study Completion Date

2020-08-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the safety of TRS01 eye drops in participants with active non-infectious anterior uveitis

.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-infectious Anterior Uveitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TRS01 low dose

Group Type EXPERIMENTAL

TRS01 eye drops

Intervention Type DRUG

Dosed four times a day (QID)

TRS01 high dose

Group Type EXPERIMENTAL

TRS01 eye drops

Intervention Type DRUG

Dosed four times a day (QID)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TRS01 eye drops

Dosed four times a day (QID)

Intervention Type DRUG

TRS01 eye drops

Dosed four times a day (QID)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older
* Able to provide informed consent, follow instructions and complete all required study visits for the duration of the study.
* Diagnosed with active non-infectious anterior uveitis requiring an increase or initiation of topical steroids for management of ocular inflammation.

An eligible subject must have:

* Non-infectious active anterior uveitis with anterior chamber cells Grade 2 or Grade 3, as specified per protocol.
* Must have vision ≥ 20/40 in the non-study eye.
* Use adequate birth control by men and women, if of reproductive potential and sexually active, as specified per protocol.

Exclusion Criteria

* Any form of infectious uveitis
* Active retinitis
* Cancer or melanoma that is actively treated with immunotherapy
* Pregnancy / lactation
* Receiving specific medication/interventions as specified per protocol
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tarsier Pharma

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Palisades Park

Palisades Park, New Jersey, United States

Site Status

San Antonio

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GADOT 20/20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.